Vitamin D supplementation in nursing home patients: randomized controlled trial of standard daily dose versus individualized loading dose regimen.

Détails

ID Serval
serval:BIB_6AA270C75B83
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Vitamin D supplementation in nursing home patients: randomized controlled trial of standard daily dose versus individualized loading dose regimen.
Périodique
Drugs and Aging
Auteur⸱e⸱s
Wijnen H., Salemink D., Roovers L., Taekema D., de Boer H.
ISSN
1179-1969 (Electronic)
ISSN-L
1170-229X
Statut éditorial
Publié
Date de publication
09/2015
Peer-reviewed
Oui
Volume
32
Numéro
5
Pages
371-378
Langue
anglais
Résumé
BACKGROUND: Supplementation of cholecalciferol 800 IU daily appears to be insufficient to raise vitamin D levels to >75 nmol/l in nursing home (NH) patients.
OBJECTIVE: Our objective was to compare the efficacy of an individualized cholecalciferol loading dose (LD) regimen and a daily dose (DD) regimen of cholecalciferol 800 IU in reaching 25-OH vitamin D (25OHD) levels >75 nmol/l.
METHODS: A total of 30 NH patients with 25OHD levels <50 nmol/l were included. Patients were randomized using the minimization method in the LD or DD group. The cholecalciferol LD, calculated with an algorithm based on serum 25OHD level and body weight, was administered in divided doses of 50,000 IU twice a week, followed by a monthly maintenance dose of either 50,000 or 25,000 IU. The DD regimen consisted of cholecalciferol 800 IU daily for 26 weeks. Serum 25OHD, calcium, creatinine, phosphate, and parathyroid hormone were measured, and 2-minute walking test, handgrip strength, and timed get up and go test were assessed at baseline (T 0), after 5 weeks (T 5), 12 weeks (T 12), and 26 weeks (T 26). The primary endpoint was the percentage of patients with 25OHD levels >75 nmol/l at T 5. Secondary endpoints were the proportion of patients with 25OHD levels >75 nmol/l at T 26, safety of LD regimen, and improvement of performance tests with normalization of vitamin D levels.
RESULTS: Median baseline 25OHD levels (interquartile range) were comparable between the 14 DD and 16 LD patients: 20.9 (15.9-29.6) and 21.7 (16.4-32.8) nmol/l, respectively. Levels of 25OHD >75 nmol/l at T 5 were reached in 79 % of the 14 LD patients, but in none of the 13 DD patients (p < 0.001). At T 26, 25OHD levels >75 nmol/l were reached in 83 % of the 12 LD patients and in 30 % of the ten DD patients (p < 0.05). Side effects or hypercalcemia were not observed. No improvement of performance tests was observed.
CONCLUSION: In NH patients with severe 25OHD deficiency, an individualized calculated cholecalciferol LD is likely to be superior to a DD of cholecalciferol 800 IU in terms of the ability to rapidly normalize vitamin D levels.
Mots-clé
Aged, Aged, 80 and over, Algorithms, Body Weight, Cholecalciferol/administration & dosage, Cholecalciferol/therapeutic use, Dietary Supplements, Endpoint Determination, Female, Hand Strength, Humans, Male, Nursing Homes, Patients, Precision Medicine/methods, Reference Standards, Treatment Outcome, Vitamin D/administration & dosage, Vitamin D/therapeutic use, Vitamin D Deficiency/complications, Vitamins/administration & dosage, Vitamins/therapeutic use, Walking
Pubmed
Web of science
Création de la notice
14/12/2015 12:09
Dernière modification de la notice
20/08/2019 14:25
Données d'usage